Anti-tumor Effects of Letrozole

REFERENCES

• Miller W.R. Estrogens and Endocrine Therapy for Breast Cancer. Estrogen and Breast Cancer, W.R. Miller. RH Landes & Co., Austin, TX 1996; 125–150
   Google Scholar
• Miller W.R. Sources of Estrogen and Sites of Biosynthesis. Estrogen and Breast Cancer, W.R. Miller. RH Landes & Co., Austin, TX 1996; 75–94
   Google Scholar
• Miller W.R. Aromatase Inhibitors in the Treatment of Advanced Breast Cancer. Cancer Treat. Rev. 1989; 16: 82–85
   Google Scholar
• Miller W.R. Aromatase Inhibitors and Breast Cancer. Cancer Treat. Rev. 1997; 23: 171–187
   PubMed Web of Science ®Google Scholar
• Miller W., Dixon J.M. Antiaromatase Agents: Preclinical Data and Neoadjuvant Therapy. Clin. Breast Cancer 2000; 1(Supp. 1)S9–S14
   PubMedGoogle Scholar
• Miller W.R. Biology of Aromatase Inhibitors: Pharmacology/Endocrinology Within the Breast. Endocr. Relat. Cancer 1999; 6: 187–195
   PubMed Web of Science ®Google Scholar
• Bhatnagar A., Miller W.R. Pharmacology of Inhibitors of Estrogen Biosynthesis. Handbook of Experimental Pharmacology, Volume: Estrogens and Antiestrogens, M. Oettel, E. Schillinger. Springer-Verlag, Berlin 1999; 223–230
   Google Scholar
• Santen R.J., Harvey H.A. Use of Aromatase Inhibitors in Breast Carcinomas. Endocr. Relat. Cancer 1999; 6: 75–92
   PubMed Web of Science ®Google Scholar
• Lonning P.E. Pharmacology of New Aromatase Inhibitors. The Breast 1996; 5: 202–208
   Web of Science ®Google Scholar
• Miller W.R., Forrest A.P.M. Oestradiol Synthesis from C19 Steroids by Human Breast Cancers. Br. Cancer 1976; 33: 116–118
   Google Scholar
• Demers L.M., Lipton A., Harvey H.A., Kambic K.B., Grossberg H., Brady C., Santen R.J. The Efficacy of CGS20267 in Suppressing Estrogen Biosynthesis in Patients with Advanced Stage Breast Cancer. J. Steroid Biochem. 1993; 44: 687–691
   Google Scholar
• Geisler J., Haynes B., Anker G., Dowsett M., Lonning P.E. Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over-Designed Study. J. Clin. Oncol. 2002; 20(3)751–757
   PubMed Web of Science ®Google Scholar
• Miller W.R. Levels and Patterns of Estrogen Within the Breast, Its Fluids and Tissues. Estrogen and Breast Cancer, W.R. Miller. RG Landes Co., Austin, TX 1996; 95–107
   Google Scholar
• Miller W.R., Telford J., Love C., Leonard R.C.F., Hillier S., Gundacker H., Smith H., Dixon J.M. Effects of Letrozole as Primary Medical Therapy on In Situ Oestrogen Synthesis and Endogenous Oestrogen Levels Within the Breast. The Breast 1998; 7: 273–276
   Web of Science ®Google Scholar
• Bonadonna G., Veronesi U., Brambilla C., Ferrari L., Luini A., Greco M., Bartoli C., Coopmans de Yoldi G., Zucali R., Rilke F., et al. Primary Chemotherapy to Avoid Mastectomy in Tumors with Diameters of Three Centimeters or More. J. Natl Cancer Inst. 1990; 82: 1539–1545
   PubMed Web of Science ®Google Scholar
• Bundred N.J., AbouElnagah G., Bramley M. Primary Medical Therapy for Breast Cancer: Clinical and Biological Aspects, M. Dowsett, A. Howell. Elsevier, Amsterdam 1999; 39–52
   Google Scholar
• Chollet P., Charrier S., Brain E., Cure H., van Praagh I., Feillel V., de Latour M., Dauplat J., Misset J.L., Ferriere J.P. Clinical and Pathological Response to Primary Chemotherapy in Operable Breast Cancer. Eur. J. Cancer 1997; 33: 862–868
   PubMed Web of Science ®Google Scholar
• Keen J.C., Dixon J.M., Miller E.P., Cameron D.A., Chetty U., Hanby A., Bellamy C., Miller W.R. The Expression of Ki-Sl and BCL-2 and the Response to Primary Tamoxifen Therapy in Elderly Patients with Breast Cancer. Breast Cancer Res. Treat. 1997; 44: 123–133
   PubMed Web of Science ®Google Scholar
• Dowsett M., Smith I.E., Powles T.J., Salter J., Ellis P.A., Johnston S.R.D., Makris A., Mainwaring P., Gregory R.K., Archer C., Chang J., Assersohn L. Primary Medical Therapy for Breast Cancer: Clinical and Biological Aspects, M. Dowsett, A. Howell. Elsevier, Amsterdam 1999; 113–126
   Google Scholar
• Dixon J.M., Love C.D.B., Bellamy C.O.C., Cameron D.A., Leonard R.C.F., Smith H., Miller W.R. Letrozole as Primary Medical Therapy for Locally Advanced and Large Operable Breast Cancers. Breast Cancer Res. Treat. 2001; 66: 191–199
   PubMed Web of Science ®Google Scholar
• Miller W.R., Anderson T.J., Hawkins R.A., Keen J., Dixon J.M. Primary Medical Therapy for Breast Cancer: Clinical and Biological Aspects, M. Dowsett, A. Howell. Elsevier, Amsterdam 1999; 89–100
   Google Scholar
• Dixon J.M., Love C.D.B., Renshaw L., Bellamy C., Cameron D.A., Miller W.R., Leonard R.C.F. Lessons from the Use of Aromatase Inhibitors in the Neoadjuvant Setting. Endocr. Relat. Cancer 1999; 6: 227–230
   PubMed Web of Science ®Google Scholar
• Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Janicke F., Miller W.R., Evans D.B., Dugan M., Brady C., Quebe-Fehling E., Borgs M. Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbBB1 and/or ErbB2 Positive, Estrogen Receptor Positive Primary Breast Cancer. J. Clin. Oncol. 2001; 19: 3808–3816
   PubMed Web of Science ®Google Scholar
• Eirmann W., Paepke S., Appfelstaedt J., et al. Preoperative Treatment of Postmenopausal Breast Cancer Patients with Letrozole: A Randomised Double-Blind Multicenter Study. Ann. Oncol. 2001; 12: 1527–1532
   PubMed Web of Science ®Google Scholar
• Gershanovich M., Chaudri H.A., Campos D., et al. Letrozole a New Aromatase Inhibitor: Randomized Trial Comparing 2.5 mg Daily, 0.5 mg Daily and Aminoglutethimide in Postmenopausal Women with Advanced Breast Cancer. Ann. Oncol. 1998; 9: 639–645
   PubMed Web of Science ®Google Scholar
• Dombernowsky P., Smith I., Falkson G., Leonard R., Panasci L., Bellmunt J., Bezwoda W., Gardin G., Gudgeon A., Morgan M., Fornasiero A., Hoffmann W., Michel J., Hatschek T., Tjabbes T., Chaudri H.A., Hornberger U., Trunet P.F. Letrozole, a New Oral Aromatase Inhibitor for Advanced Breast Cancer: Double-Blind Randomized Trial Showing a Dose Effect and Improved Efficacy and Tolerability Compared with Megestrol Acetate. J. Clin. Oncol. 1998; 16: 453–461
   PubMed Web of Science ®Google Scholar
• Mouridsen H., Gershanovich M., Monnier A., Boni C., Chaudri H., Staffler B., Dugan M. Letrozole Is Superior to Tamoxifen as First-Line Hormonal Treatment of Post-menopausal Women with Locally Advanced or Metastatic Breast Cancer. J. Clin. Oncol. 2001; 19: 2596–2606
   PubMed Web of Science ®Google Scholar